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Abstract HIV-associated neurocognitive disorders (HAND) af-
fect up to 50 % of HIV-infected adults, independently predict
HIV morbidity/mortality, and are associated with neuronal dam-
age and monocyte activation. Cerebrospinal fluid (CSF) neuro-
filament subunits (NFL, pNFH) are sensitive surrogate markers
of neuronal damage in several neurodegenerative diseases. In
HIV, CSF NFL is elevated in individuals with and without cog-
nitive impairment, suggesting early/persistent neuronal injury
duringHIVinfection.Although individualswith severe cognitive
impairment (HIV-associated dementia (HAD)) express higher
CSF NFL levels than cognitively normal HIV-infected individ-
uals, the relationships between severity of cognitive impairment,
monocyte activation, neurofilament expression, and systemic in-
fection are unclear. We performed a retrospective cross-sectional
study of 48 HIV-infected adults with varying levels of cognitive
impairment, not receiving antiretroviral therapy (ART), enrolled
in the CNS Anti-Retroviral Therapy Effects Research (CHAR
TER) study. We quantified NFL, pNFH, and monocyte activa-
tion markers (sCD14/sCD163) in paired CSF/plasma samples.
By examining subjects off ART, these correlations are not con-
founded by possible effects of ARTon inflammation and neuro-
degeneration. We found that CSF NFL levels were elevated in
individuals with HAD compared to cognitively normal or mildly
impaired individuals with CD4+ T-lymphocyte nadirs ≤200. In
addition, CSFNFL levels were significantly positively correlated
to plasma HIV-1 RNA viral load and negatively correlated to
plasma CD4+ T-lymphocyte count, suggesting a link between
neuronal injury and systemic HIV infection. Finally, CSF NFL
was significantly positively correlatedwith CSF pNFH, sCD163,
and sCD14, demonstrating that monocyte activation within the
CNS compartment is directly associated with neuronal injury at
all stages of HAND.
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Introduction
HIV-associated neurocognitive disorders (HAND) are a com-
mon complication of HIV infection in the era of combined
antiretroviral therapy (cART) that independently predict overall
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morbidity and mortality (Ellis et al. 2007; Ellis et al. 1997;
Valcour et al. 2011; Vivithanaporn et al. 2010). The clinical
sub-syndromes of HAND vary in severity of cognitive impair-
ment and associated functioning and include asymptomatic
neurocognitive impairment (ANI), mild neurocognitive disorder
(MND), and HIV-associated dementia (HAD) (Antinori et al.
2007). Although HIV does not infect neurons, cognitive impair-
ment in HIV is associated with pathological evidence of neuro-
nal damage (synaptic loss, dendritic simplification), as well as
infection and activation of central nervous system (CNS) infil-
trating monocyte-derived macrophages (Cherner et al. 2002;
Ellis et al. 2007; Masliah et al. 1997). Up to 30 % of HIV-
infected individuals qualify for a diagnosis of ANI, 10–30 %
forMND, and 2–8% forHAD (Ellis et al. 2007;McArthur et al.
2010); each diagnosis is based on neurocognitive testing and
assessments of daily functioning in the absence of pre-existing
or confounding diagnoses that may independently result in cog-
nitive impairment. The temporal progression among these sub-
types of HAND is not consistently linear, although they appear
to be clinically and pathologically related (Ellis et al. 2007;
McArthur et al. 2010; Tan and McArthur 2012). Individuals
with ANI have an increased risk of progression to functional
decline compared to neurocognitively normal HIV-infected in-
dividuals (Ellis et al. 2007; Grant et al. 2014; Heaton et al. 2012;
McArthur and Brew 2010; McArthur et al. 2010). In addition,
mild, moderate, and severe cognitive impairment has been as-
sociated with synaptodendritic injury (Ellis et al. 2007; Masliah
et al. 1997; McArthur et al. 2010; Tan and McArthur 2012),
although the relationship between pathological abnormalities
and severity of cognitive impairment has not been fully defined
(Gelman et al. 2012).
Neurofilaments (NFs) are structural proteins specific to neu-
rons that are released into the cerebrospinal fluid (CSF) and
blood following axonal disruption or degeneration (Gresle
et al. 2011; Julien 1999; Pasol et al. 2010). The neurofilament
core chains are of low,medium, or highmolecular weight (NFL,
NFM, NFH, respectively) with varying degrees of phosphory-
lation; these proteins are expressed in a stereotypic and phylo-
genetically conserved manner throughout neuronal develop-
ment (Mellgren et al. 2007; Szaro and Strong 2010). Elevations
in CSF NFL are a sensitive surrogate marker of neuronal dam-
age, as evidenced by pathological white matter changes, in sev-
eral neurodegenerative diseases, including Alzheimer’s disease,
subcortical vascular dementia (Norgren et al. 2003), amyotro-
phic lateral sclerosis (ALS), and multiple sclerosis (MS)
(Malmestrom et al. 2003; Rosengren et al. 1996). In HIV infec-
tion, CSF NFL levels are elevated both in early and later infec-
tion in individuals with and without neurocognitive impairment
(Jessen Krut et al. 2014; Peluso et al. 2013), although levels are
highest in HAD (Abdulle et al. 2007; Gisslen et al. 2007;
Mellgren et al. 2007). Moreover, CSF NFL levels increase with
cART interruption and decrease with cART initiation (Abdulle
et al. 2007); neurocognitive performance improves in HAD in
parallel with CSF NFL drop (Mellgren et al. 2007). Phosphor-
ylated NFH (pNFH), a more protease-resistant NF, has also
been examined in multiple pathologies involving neuronal inju-
ry. Specifically, serum pNFH is elevated in amyotrophic lateral
sclerosis (ALS) (Ganesalingam et al. 2011), optic neuritis (Pasol
et al. 2010), and following acute ischemic stroke (Sellner et al.
2011). In addition, CSF and serum NFH concentrations corre-
late with each other in ALS (Ganesalingam et al. 2011). Neither
CSF nor serum/plasma pNFH levels have been examined in
HIV infection. In multiple sclerosis, CSF pNFH but not CSF
NFL levels are higher in progressive patients compared with
those in relapsing/remitting patients. However, CSF NFL but
not CSF pNFH levels predict early clinical disease progression
from a first-time demyelinating attack to relapsing/remitting
disease (Gresle et al. 2011; Petzold et al. 2005). Therefore, ele-
vations in CSF NFL and pNFH, while both reflecting axonal
damage,might have different associations with disease subtypes
and/or disease progression, thus supporting separate investiga-
tion of each neurofilament subunit in HIV-infected individuals.
Positive correlations between CSF NFL and CSF neopterin
(a marker of intrathecal monocyte/macrophage activation)
have been described in individuals with HAD (Abdulle et al.
2007; Mellgren et al. 2007), supporting previous evidence that
axonal degeneration is associated with such activation (Ryan
et al. 2001). Although plasma sCD163 has been correlated
with HAND subtype (Burdo et al. 2013), the relationship be-
tween plasma monocyte activation markers, CSF NF iso-
forms, and HAND subtype has not been defined. Among the
monocyte activation markers is membrane-bound CD14, a
receptor for lipopolysaccharide. Activation of CD14 is asso-
ciated with CD14 cleavage and release from the cell mem-
brane in a soluble form (sCD14). Notably, plasma sCD14
levels independently predict mortality (Ryan et al. 2001;
Sandler et al. 2011) and impaired neurocognitive test perfor-
mance in HIV-infected subjects (Lyons et al. 2011). In addi-
tion, plasma sCD14 is elevated in HIV-infected subjects with
cerebral atrophy compared to those without cerebral atrophy
(Ryan et al. 2001). Thus, sCD14 is an excellent candidate
biomarker of monocyte/macrophage activation associated
with HIV-induced neurodegeneration. Similar to CD14,
CD163, a monocyte-associated hemoglobin/haptoglobin
complex scavenger receptor, is cleaved and shed from activat-
ed monocyte/macrophages in a soluble form, sCD163 in in-
flammatory states (Møller 2012). Plasma sCD163 levels are
elevated HIV-infected subjects, particularly those with cogni-
tive impairment (Burdo et al. 2011; Burdo et al. 2013), and
plasma levels decrease with cART in parallel with HIV RNA
(Burdo et al. 2011). In addition, CD163+ monocyte/
macrophages accumulate in perivascular brain regions in in-
dividuals with HIV encephalitis (Fischer-Smith et al. 2008a;
Roberts et al. 2004). The number of perivascular CD163+
monocyte/macrophages is positively correlated with plasma
HIV load (Fischer-Smith et al. 2008b), suggesting trafficking
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of peripherally activated monocytes to perivascular areas in
the brain. Finally, elevated plasma sCD163 levels have been
demonstrated in cognitively impaired HIV-infected individ-
uals compared with non-impaired individuals (Burdo et al.
2013), although whether such levels are correlated with ex-
pression of markers of neurodegeneration is not known.
To determine the relationship between neurodegeneration
and monocyte/macrophage activation in HAND, as assessed
by soluble biomarkers, we determined the correlations among
levels of CSF neurofilament isoforms (NFL, pNFH), sCD14,
and sCD163 across different stages of HAND and cognitively
normal HIV-infected adult controls. We then examined asso-
ciations of soluble biomarker levels with markers of systemic
infection (plasma HIV-1 RNAviral load, CD4+ T-lymphocyte
count) and with global and domain-specific cognitive impair-
ment and HAND stage.
Methods
Study design and setting
We performed a retrospective cross-sectional study using data
and biological samples (plasma, CSF) from 48 HIV-infected
adults enrolled in the CNS HIVAnti-Retroviral Therapy Ef-
fects Research (CHARTER) cohort of the NIMH/NINDS/
NIH. Characteristics of the CHARTER cohort are described
elsewhere (Heaton et al. 2010). CHARTER is an ongoing,
observational cohort study of HIV-infected persons enrolled
between 2003 and 2007 from six US university-affiliated HIV
treatment centers. Enrolling 1561 HIV+ subjects at baseline,
the study was designed to assess the frequency and severity of
HAND and the specific contributions of HIV versus HIV-
associated comorbidities to neurocognitive impairment. Inclu-
sion criteria for the CHARTER study were broad, but individ-
uals with severe comorbid psychiatric, medical, or neurolog-
ical disorders deemed likely to adversely affect cognitive
functioning were excluded, as were HIV-negative subjects.
Our study used data and samples from 48 CHARTER subjects
(15 each from ANI and MND subgroups, 3 HAD subjects,
and 15 neurocognitively normal (NCN) HIV-infected sub-
jects). The cohort included men and women aged 18–65 years
who were ART naïve or currently off of ART and who
underwent successful lumbar puncture, venipuncture, and
neuropsychological testing. Subjects with a history of CNS
opportunistic infection, trauma, epilepsy, MS, known causes
of mental retardation, dementia, or active psychotic illness
were excluded.
Data collection
Original data collection for the CHARTER cohort was ap-
proved by the Human Subjects Protection Committees of each
participating institution. All subjects provided written consent
to participate in the CHARTER study. Data were originally
obta ined through comprehens ive neuromedica l ,
neurocognitive, psychiatric, and functional evaluations and
collection of blood and urine samples. Collection of CSF
was through lumbar puncture (Heaton et al. 2010). The de-
identified data and biological samples for this substudy were
obtained with permission of the CHARTER steering commit-
tee. Because the dataset and samples were de-identified and
because our substudy did not involve patient contact, The
Children’s Hospital of Philadelphia institutional review board
determined (November 21, 2012) that this study did not qual-
ify as human subject research.
Laboratory assessments
HIV infection was diagnosed by ELISA with Western blot
confirmation. Clinical laboratory assessments, including com-
plete blood counts, chemistry panels, rapid plasma regain
(RPR), hepatitis C virus (HCV) antibody, and flow cytometry
for CD4+ T-lymphocyte count were performed at each CHAR
TER site’s Clinical Laboratory Improvement Amendments
(CLIA)-certified, or CLIA equivalent, medical center labora-
tory. Plasma HIV loads (viral loads) were quantified by RT-
PCR ultrasensitive assay (nominal lower quantitation limit
50 copies/mL; Amplicor®, Roche Diagnostic Systems, India-
napolis, IN) in a central lab (Heaton et al. 2010).
Biomarkers were measured in triplicate by validated, com-
mercially available 96-well plate ELISAs on stored, frozen
samples (−80C). Paired CSF/plasma samples were assayed
for NFL (UmanDiagnostics AB, limit of detection 31 ng/
mL) and pNFH (Biovendor ca ta log number RD
191138300R, limit of detection 23.5 pg/mL); NFL and pNFH
were detected only in CSF samples. sCD14 and sCD163 were
assayed in paired CSF/plasma samples (R&D Systems, cata-
log number DC140, limit of detection 125 pg/mL sCD14 and
Trillium Diagnostics, IQP-383, limit of detection 0.23 ng/mL
sCD163).
Neurocognitive assessments
All CHARTER study subjects completed a comprehensive
neuropsychological test battery assessing seven cognitive do-
mains commonly affected in HIV infection (verbal fluency,
executive functioning, speed of information processing, learn-
ing, recall, working memory, and motor skills). Raw test
scores were converted to demographically adjusted T-scores
using the best available normative data accounting for age,
sex, ethnicity, and education. Functional impairment was
assessed using the Patient’s Assessment of Own Functioning
Inventory (PAOFI) and instrumental activities of daily living
(IADL) questionnaire (Heaton et al. 2010). A global perfor-
mance score was determined as previously described (Carey
J. Neurovirol. (2015) 21:439–448 441
et al. 2004; Woods et al. 2004). HAND status was classified
according to Frascati criteria (Antinori et al. 2007).
Data analysis and statistical methods
Data were analyzed using Stata version 12.1 (StataCorp, Col-
lege Station, Texas, 2011). Continuous variables were de-
scribed using median and intraquartile range (IQR), and inter-
group differences were evaluated using Kruskal-Wallis tests
and Wilcoxan rank-sum tests. Categorical variables were de-
scribed using counts and percents, and intergroup differences
were compared using the chi-square test. Spearman’s correla-
tion coefficients were used for correlations between bio-
markers. Statistical significance was determined a prior as a
two-tailed p value <0.05.
Results
To avoid any potential confounding effects of ARTon expres-
sion of selected biomarkers of inflammation and neuronal
injury, we selected a study cohort of individuals currently
not receiving ART. Cohort demographics, medical, and labo-
ratory characteristics are summarized in Table 1. Among the
48 subjects examined, 75 % were male, and 53 % were Afri-
can American. The median age was 39.5 (IQR 36–47.5, range
19–62). Only plasma CD4+ T-lymphocyte count and plasma
HIV-1 RNA differed across HAND subtypes: CD4+ T-
lymphocyte count was lower and plasma HIV-1 RNA was
higher in HAD when compared with ANI, MND, and
neurocognitively normal controls (p=0.046, p=0.038,
respectively). Thus, as expected, our subjects with HAD dem-
onstrated greater immune deficiency and poorer systemic viral
control than those without HAD as has been previously dem-
onstrated in ART-naïve patients (McArthur and Brew 2010;
McArthur et al. 2010). Finally, only one subject (ANI) was
actively using illicit drugs (marijuana, opioids) during this
study.
To determine the associations between neuronal injury,
monocyte/macrophage activation, and the severity of HAND,
we first examined expression of neurofilament isoforms NFL
and pNFH in CSF and expression of sCD163 and sCD14 in
both CSF and plasma across the different sub-types of HAND.
Among individuals with CD4+ T-lymphocyte nadirs ≤200,
CSF NFL levels were significantly elevated in individuals with
HAD compared with neurocognitively normal subjects and
those with MND (Fig. 1a). There were no differences among
HAND subtypes in levels of CSF NFL across all CD4+
T-lymphocyte nadirs (Fig. 1b), CSF pNFH (Fig. 1c, d), CSF/
plasma sCD14, or CSF/plasma CD163 (data not shown). In
addition, CSF NFL levels did not significantly differ across
HAND subtypes by current CD4+ T-lymphocyte count among
neurocognitively normal subjects in contrast to another recent
study (Peterson et al. 2013). Finally, because our cohort did not
include HIV-negative individuals, we compared absolute NFL
levels with historical age-specific controls using the same NFL
ELISA assay (UmanDiagnostics, AB) (Jessen Krut et al. 2014).
Using these historical controls, we found that 10/15
neurocognitively normal, 11/15 ANI, 11/15 MND, and 2/3
HAD subjects demonstrated elevated CSFNFL levels, suggest-
ing ongoing subclinical neuronal injury in HIV-infected indi-
viduals regardless of neurocognitive status.
Table 1 Demographic and clinical characteristics of the study population
Characteristica All, n=48 NCN, n=15 ANI, n=15 MND, n=15 HAD, n=3 pb
Male sex 36 (75) 12 (80) 9 (60) 12 (80) 3 (100) 0.362
Black race 25 (53) 8 (57) 7 (47) 9 (60) 1 (33) 0.777
Age (years) 39.5 (36–47.5) 44 (36–49) 38 (31–40) 40 (35–48) 47 (38–50) 0.392
Duration of HIV (months) 98 (29–157) 131 (71–186) 99 (11–122) 98 (23–162) 34 (2–234) 0.616
Education (years) 12 (11–13) 13 (12–15) 11 (10–12) 12 (9–14) 13 (12–14) 0.102
HCV positive 14 (31) 5 (33) 6 (40) 3 (20) 0 (0) 0.420
RPR positive 5 (10) 1 (7) 1 (7) 3 (21) 0 (0) 0.538
CD4 nadir ≤200 14 (29) 5 (33) 3 (20) 4 (27) 2 (67) 0.420
Plasma CD4 <50 5 (10) 1 (7) 1 (7) 1 (7) 2 (67) 0.046
50–199 5 (10) 1 (7) 2 (13) 2 (13) 0 (0) –
200–349 7 (15) 0 (0) 3 (20) 3 (20) 1 (33) –
≥350 31 (65) 13 (87) 9 (60) 9 (60) 0 (0) –
Plasma HIV–1 RNA (log10 copies/mL) 4.34 (3.66–4.87) 3.83 (3.15–4.06) 4.68 (3.97–5.04) 4.54 (3.93–5.08) 5.53 (3.12–6.16) 0.038
CSF HIV–1 RNA (log10 copies/mL) 2.45 (1.70–3.20) 1.83 (1.70–3.20) 2.84 (1.70–3.20) 2.86 (2.01–3.41) 1.70 (1.70–2.35) 0.330
a Categorical variables are described using n (%). Continuous variables are described using median (IQR)
b p values to compare characteristics among different subgroups of HAND were calculated using chi-square tests for categorical variables and Kruskal-
Wallis tests for continuous variables
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Both CSF and plasma expression of sCD163 and sCD14
correlated within compartments (Fig. 2a, b), as did CSF NFL
and pNFH (data not shown). The only other similar intra-
compartment correlations of monocyte activation markers we
are aware of in theHIV literature have demonstrated a correlation
between plasma sCD163 and CSF neopterin (Burdo et al. 2013)
and plasma sCD163 and plasma sCD14 (Burdo et al. 2011). The
strength and significance of the correlation shown in Fig. 2 sug-
gests that both sCD163 and sCD14 similarly reflect monocyte
activation in the CSF (and either may be used with confidence as
a CSF marker of monocyte activation) and supports the conclu-
sion that these markers are predictably detecting monocyte/
macrophage activation and neuronal injury in these subjects.
Next, to assess the relationship between CSFmarkers of neu-
rodegeneration, monocyte activation, and systemic HIV infec-
tion and to determinewhethermarkers ofmonocyte/macrophage
activation correlate with neuronal injury in HAND, each of the
above candidate biomarkers was examined in association with
each other and with plasma HIV-1 RNAviral load and CD4+ T-
lymphocyte count in all subjects, regardless of cognitive impair-
ment. Here, CSF NFL was negatively correlated with CD4+ T-
lymphocyte count (Fig. 3a) and positively correlatedwith plasma
HIV-1 RNA viral load (Fig. 3b), suggesting a relationship be-
tween neuronal damage and systemic HIV infection. CSF pNFH
did not demonstrate the same correlations with markers of sys-
temic HIV infection. Additionally, CSF NFL and pNFH levels
Fig. 1 CSF NFL is elevated in
individuals with HAD and a
history of immunosuppression.
NFL concentrations in the CSF of
HIV+ a individuals with CD4
count nadir ≤200 and b
individuals with any CD4 count
nadir. pNFH concentrations in the
CSF of HIV+ c individuals with
CD4 count nadir ≤200 and d
individuals with any CD4 count
nadir. Data is presented as median
and IQRwith differences between
groups evaluated using Kruskal-
Wallis tests
Fig. 2 Monocyte activation
markers intra-compartmentally
correlate within the CSF and
plasma. Correlations between the
monocyte markers sCD163 and
sCD14 within the a CSF and b
plasma across all HIV-infected
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correlated strongly and positively with CSF sCD163 (Fig. 4a, b)
and CSF sCD14 (Fig. 4c, d), thus indicating that monocyte/
macrophage activation within the CNS compartment is tightly
linked to neuronal injury. In contrast to CSF expression, plasma
expression of sCD14 and sCD163 did not correlate with CSF
NFL or CSF pNFH. This suggests either no association between
systemic monocyte/macrophage activation and CNS neuronal
injury in this untreated cohort or a low level of sensitivity of
plasma sCD14 and sCD163 detection as biomarkers for CNS
neuronal injury in comparison with CSF sCD14 and sCD163.
Examination of biomarker associations with cognitive test-
ing subdomain and global cognitive scores demonstrated that
CSF pNFH was significantly higher in subjects with impaired
speed of information processing (median CSF pNFH 103 pg/
mL in unimpaired compared to 371 pg/mL in impaired sub-
jects, total CSF pNFH range 96–1144 pg/mL, p=0.018) and
memory (median CSF pNFH 103 pg/mL in unimpaired com-
pared to 220 pg/mL in impaired subjects, p=0.021) compared
to unimpaired subjects, although the magnitude of this effect
was small. There were no significant correlations among NFL,
Fig. 3 CSF NFL correlates
negatively with plasma CD4+
T-lymphocyte count and
positively with HIV-1 RNA load.
Correlations between CSF NFL
concentrations and plasma a
CD4+ T-lymphocyte count and b
HIV-1 RNA load in all
HIV-infected individuals with and
without HAND. Correlations





activation markers within the
CSF. Correlations between
sCD163 and a NFL and b pNFH
and between sCD14 and c NFL
and d pNFH within the CSF of all
HIV-infected individuals with and
without HAND. Correlations
were analyzed using Spearman’s
correlation coefficients
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plasma/CSF sCD14, or sCD163 and subdomain global deficit
scores or impairment (data not shown).
Finally, to investigate whether hepatitis C virus (HCV)
serostatus affected the relationships described above between
the neurofilament isoforms, monocyte activation markers, and
HAND subtypes, we performed an exploratory analysis ex-
amining concentrations of each of these markers across
HAND for HCV+ and HCV− subjects separately. No statisti-
cally significant differences were found (data not shown). To
determine whether a differential level of peripheral or central
monocyte activation was present in HCV+ versus HCV− sub-
jects, we then compared monocyte activation marker concen-
trations between these populations. After manually removing
outlier values, none of the markers examinedwas significantly
different between HCV+ and HCV− subjects (data not
shown).
Discussion
We have demonstrated a strong correlation between CSF
markers of neuronal damage (NFL, pNFH) and monocyte/
macrophage activation (sCD14 and sCD163) in an unselected
cohort of viremic HIV-infected individuals not receiving ART.
No correlations between CSF NFL/pNFH and plasma sCD14
and sCD163 were demonstrated. In addition, plasma sCD163
did not vary significantly across different HAND subtypes, in
contrast with a previous study of virologically suppressed in-
dividuals on ART (Burdo et al. 2013). However, plasma
sCD163 levels in our cohort were higher than those observed
in the previous study, which could reflect other factors con-
tributing to monocyte/macrophage activation in this cohort,
including perhaps uncontrolled peripheral HIV infection, co-
infection with HCV, or syphilis in some individuals (Table 1).
Notably, there were no observed differences which correlated
with HCV serostatus in this cohort. Nonetheless, our study
clearly demonstrates that CNS monocyte/macrophage activa-
tion, as measured by CSF sCD163 and sCD14 is strongly
correlated with neuronal injury, and based on current under-
standing of HIV neuropathophysiology, this likely represents
a causal association.
The possible association between CSF neurofilaments
and severity of cognitive impairment in HIV-infected indi-
viduals has not been fully described and involves complex
and numerous variables. Similar to others (Abdulle et al.
2007; Gisslen et al. 2007; Mellgren et al. 2007), we found
that CSF NFL was significantly elevated in HAD subjects
compared with those with milder (MND) or no cognitive
dysfunction; this relationship was observed only in individ-
uals with CD4 count nadirs ≤200, which is strongly associ-
ated with an increased risk for HAND (Heaton et al. 2010;
McArthur and Brew 2010; McArthur et al. 2010). Recent
studies have demonstrated significant elevations in CSF
NFL in individuals with acute HIV infection and in HIV-
infected individuals without cognitive impairment (Jessen
Krut et al. 2014; Peluso et al. 2013), although higher levels
are observed in individuals with HAD, the most severe form
of HAND. Elevated CSF NFL in acute HIV infection has
also been associated with low N-acetylaspartate/creatine ra-
tios (another indicator of neuronal injury) in cortex and
white matter, as measured by brain magnetic resonance
spectroscopy (Peluso et al. 2013). In contrast, our study
failed to demonstrate significant elevations of CSF NFL in
ANI and MND individuals when compared with
neurocognitively normal HIV-infected individuals, although
we do not have a seronegative control group to determine
whether CSF NFL is elevated in our seropositive
neurocognitively normal control group. In examining previ-
ously published age-specific normative data from 107 HIV-
uninfected subjects using the same ELISA platform (Jessen
Krut et al. 2014), it does indeed appear that a significant
proportion of our neurocognitively normal, ANI, and MND
subjects had NFL elevations compared to uninfected con-
trols. These data support the conclusion that some untreated
subjects have ongoing subclinical CNS injury. This conclu-
sion is inherently limited by the use of historical controls.
Thus, although CSF NFL can be considered to be sensitive
marker of neuronal injury in the CNS in HIV infection,
whether it reliably predicts or correlates with the severity
of neuronal injury and neurocognitive impairment remains
undefined. This is clearly an important gap in our under-
standing of the significance of the relative degree of neuro-
nal injury in determining the presence and/or severity
of symptoms of cognitive dysfunction in HIV infection.
Our data suggest that CSF pNFH levels in individuals
with HAND differ in comparison with CSF NFL levels.
While CSF pNFH did not vary significantly across the dif-
ferent HAND sub-types, on cognitive testing subdomain as-
sessment, we demonstrated significant associations with
CSF pNFH and impaired speed of information processing
and memory. However, the magnitude of effect was small.
Speed of information processing is dependent on multiple
neurologic pathways and therefore may be nonspecifically
affected compared to other, more localizable subdomains. In
addition, CSF pNFH had an even stronger correlation with
CSF markers of monocyte activation compared to CSF NFL,
suggesting that these different neurofilament isoforms may
represent distinct neuronal injury pathways with ultimately
different clinical implications.
Our study showed no significant correlation between CSF
NFL level and current CD4 count among neurocognitively
normal HIV-infected subjects as demonstrated in previous
studies (Abdulle et al. 2007; Peterson et al. 2013), perhaps
reflecting a sample size too small to stratify into CD4 sub-
group ranges. However, our data was significant for a negative
correlation between CSF NFL and plasma CD4+ T-
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lymphocyte count across all strata of cognitive impairment, as
well as a positive correlation between CSF NFL and plasma
HIV-1 RNA viral load. Taken together, these data suggest
more neuronal injury in more advanced (or poorly controlled)
systemic infection and may suggest a part of a mechanistic
link to the clinical observation that low CD4+ T-lymphocyte
count and high viral load are risk factors for HAD in untreated
HIV infection. Notably, there was not a similar correlation
between CSF pNFH and the same plasmamarkers of systemic
HIV infection.
Because identifying a valid plasma biomarker for neuronal
injury and/or HAND in HIV-infected individuals is still an
unmet need, we considered the potential usefulness of neuro-
filament isoforms as such biomarkers. Published studies indi-
cate that NFL is quickly proteolytically degraded in blood
specimens, while pNFH is more protease resistant (Gresle
et al. 2011). Based on prior investigations demonstrating se-
rum pNFH elevation in other neurodegenerative diseases
(Ganesalingam et al. 2011; Pasol et al. 2010; Sellner et al.
2011), serum pNFH could serve as a biomarker for neurode-
generation in the brain and/or spinal cord, each of which is
affected in many individuals with HIV infection. Analyses of
serum neurofilament isoforms in HIV infection have not been
reported. However, despite demonstrating pNFH in CSF sam-
ples from our cohort, we failed to detect pNFH in matched
plasma samples.
About one third of our overall study population was
HCV positive, consistent with other estimates in adult
HIV-infected populations (Letendre et al. 2005; Sherman
et al. 2014). However, HCV was not present in any subject
with HAD. Prior literature suggests that individuals co-
infected with both HIV and HCV have worsened cognitive
impairment compared to HIV infection alone (Clifford et al.
2005; Garvey et al. 2012). Mechanistically, HCV replicates
in CD68+ macrophages of autopsied HIV-infected brain
tissue (Wilkinson et al. 2009) and is associated with in-
creased macrophage expression of pro-inflammatory cyto-
kines (Wilkinson et al. 2010). Coinfection with HCV and
HIV may therefore affect neurocognitive status via its ef-
fects on monocyte/macrophage activation (Gill and Kolson
2014). However, in this study, we did not observe a differ-
ence in monocyte activation marker concentrations between
HCV+ and HCV− subjects, nor did we observe a differ-
ence in neurofilament isoform concentrations or monocyte
activation marker concentrations in HCV+ and HCV− sub-
jects when analyzed across the spectrum of HAND. Wheth-
er these findings are truly representative of HIV/HCV co-
infection neuropathology, or if they were limited by our
sample size or another confounding factor not accounted
for in these associations is unclear.
Our study had several limitations. First, because ART is
now widely distributed, recruiting ART-free individuals is
particularly difficult; our study therefore included a small
cohort size (n=48) with few HAD subjects (n=3). Thus,
sub-analyses with even smaller numbers (e.g., the relation-
ship between HAND and CSF NFL among patients with
CD4 count nadir <200) may be underpowered and have
limited potential significance. These data are consistent
with other prior reports though, and the possible effect of
a profound immunosuppression on these relationships re-
quires further investigation. Second, because this was a
cross-sectional correlation study, factors confounding the
relationship between monocyte/macrophage activation and
HAND status are not accounted for in statistical associa-
tions. However, relevant covariates were equivalent across
the different subtypes of HAND, except for CD4+ T-
lymphocyte count and viral load, which are known risk
factors for HAD. In addition, causality cannot be inferred
in a cross-sectional study. Finally, by including only HIV-
infected viremic subjects not receiving ART, we might ob-
scure relevant associations between plasma monocyte/
macrophage activation and neurodegeneration because of
high levels of plasma monocyte/macrophage activation in
untreated, viremic subjects. Nonetheless, we have eliminat-
ed the possibility of unanticipated effects of ART on in-
flammation and neurodegeneration.
In summary, we have demonstrated a positive correlation
between expression of CSF neurofilament isoforms and
CSF sCD14 and sCD163 in viremic HIV-infected individ-
uals not receiving ART, thus directly linking CNS
monocyte/macrophage activation with neuronal injury. Fu-
ture studies are necessary to determine whether this rela-
tionship is specific to HIV neuropathogenesis, or if it is
observed in other neuroinflammatory disorders as well. Fur-
thermore, sCD14 and sCD163 levels are highly correlated
in CSF and plasma, suggested that monocyte/macrophage
activation can reliably be detected by ELISA in such stored
tissue specimens. We have also confirmed that severe CD4
depletion (a risk factor for HAD) is associated with elevat-
ed CSF NFL levels at the time of diagnosis of HAD and
that elevated CSF NFL levels are highly correlated with
low CD4+ T-lymphocyte counts and high plasma HIV-1
RNA viral load, suggesting a link between neuronal injury
and systemic HIV infection. A previous study has sug-
gested that CSF NFL can serve as a predictive biomarker
for HAD in individuals not receiving ART (Gisslen et al.
2007). Whether CSF NFL is a sensitive predictor of risk
for HAND subtypes, and whether sCD14 and sCD163
might also have predictive value on later development/
progression of HAND in viremic versus aviremic ART-
experienced individuals remains to be determined. Finally,
we have demonstrated somewhat different correlations of
NFL and pNFH with respect to cognitive measurements,
suggesting that the different neurofilament isoforms may
represent distinct neuronal injury pathways in HIV
neuropathophysiology.
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